HRT Financial’s Seres Therapeutics MCRB Stock Holding History

HRT Financial’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-62,900	Closed	-$935K	–	4347
2025 Q4	$935K	Buy	+62,900	New	+$1.1M	﹤0.01%	1763

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's MCRB Position: Q1 2025 in Review

HRT Financial sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 1,343 shares — an estimated $22K sold.

HRT Financial first reported a position in MCRB in Q2 2019 and held it in 9 quarters. The position peaked at $3.38M in Q4 2021. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

HRT Financial reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
HRT Financial sold 1,343 Seres Therapeutics shares in Q1 2025, an estimated $22K.
HRT Financial first reported a position in Seres Therapeutics in Q2 2019 and held it in 9 quarters.
HRT Financial's Seres Therapeutics position peaked at $3.38M in Q4 2021.
63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.